IBEX earnings beat by $0.06, revenue topped estimates

IBEX reported Q2 EPS of $0.85, beating the $0.79 consensus by $0.06, while revenue of $164.3M exceeded estimates of $153.38M by $10.92M. The company guided Q1 2027 revenue to $168M-$170M versus $161.38M consensus and FY2027 revenue to $700M-$715M versus $678.51M expected. Shares had closed at $37.26 and were up 20.5% over three months and 22.32% over 12 months, supported by the earnings beat and above-consensus outlook.

Analysis

The key investable signal is not the quarterly beat but the magnitude of the forward revenue reset: management is now framing a growth trajectory materially above the prior sell-side base, creating room for FY27 consensus revisions and a multiple re-rating if incremental revenue converts to EBITDA rather than being offset by delivery and wage costs. With the shares already materially ahead of the market over the past quarter, the next leg requires evidence that new programs carry stable pricing and that customer-experience outsourcing demand is broad-based rather than concentrated in a small number of client ramps.

IBEX could outperform larger CX/BPO peers such as TTEC and Concentrix (CNXC) if its smaller revenue base allows it to win AI-enabled customer-service transitions without the legacy-seat cannibalization facing incumbents. Conversely, generative AI is a two-sided risk: it can lift IBEX's productivity and defend margins, but customers may demand that productivity benefit through lower pricing, limiting the earnings conversion investors are likely to extrapolate from the revenue guide. The relevant 6-18 month question is whether automation raises revenue per agent/program or simply reduces the addressable labor pool.

Near term, a modest positive revision cycle is likely over the next 30-60 days given the gap between management's outlook and published estimates. However, IBEX is likely more sensitive than mega-cap outsourcing peers to any deterioration in consumer-facing client volumes or a stronger dollar/wage inflation shock; a revenue guide beat without margin expansion would be insufficient to sustain a premium valuation. Falsify the constructive thesis if the next report shows organic growth decelerating below management's implied run-rate, adjusted EBITDA margin contracting, or FY27 guidance reverting toward the prior consensus range.

Key Decisions for Investors

• Initiate a tactical long IBEX over a 1-3 month horizon only on confirmation that post-earnings liquidity can support institutional sizing; target further estimate revisions following the guidance reset, with a stop if the stock closes below the pre-results support range or management fails to disclose margin conversion.
• Prefer a relative-value expression: long IBEX / short TTEC or CNXC in equal beta-adjusted dollars for 3-6 months. The thesis is that IBEX's growth reset and lower legacy exposure can drive relative earnings revisions; exit if IBEX's next-quarter revenue growth does not exceed the peer median or if margins weaken materially.
• Do not chase a standalone long after a sharp gap higher without EBITDA and client-concentration detail. Set an alert for the next filing/call: confirmation of expanding adjusted EBITDA margin and durable bookings would justify adding; evidence that guidance reflects a one-time client ramp would convert the name to a fade candidate.
• Monitor US labor-cost indicators and customer-service automation announcements over the next two quarters. A rising wage environment with no corresponding margin expansion is a direct downside catalyst, while verified AI-led productivity gains that preserve pricing would support a 6-18 month re-rating.